Trial Profile

An Open-label, Dose-escalation Phase Ib/II Clinical Trial of Recombinant Oncolytic Herpes Simplex Virus Type II (OH2) Therapeutic Injection (Vero Cell) for Human Use (rHSV2hGM-CSF) in Combination With Recombinant Oncolytic Herpes Simplex Virus Type II (BS006) Therapeutic Injection (Vero Cell) for Human Use (oHSV2-PD-L1/CD3-BsAb) for Advanced Solid Tumors.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BS-006 (Primary) ; OH 2 (Primary)
Indications Biliary cancer; Carcinoma; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions
Sponsors Binhui Biopharmaceutical

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com